Exciting News from NewAmsterdam Pharma Company N.V.
Introduction
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”) has announced the commencement of an underwritten public offering of $300.0 million of the Company’s ordinary shares, nominal value €0.12 per share, and pre-funded warrants to purchase Ordinary Shares. This Offering will provide a significant boost to the Company’s ongoing efforts to develop oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol.
Details of the Offering
All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of Ordinary Shares. The proposed Offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or terms of the proposed Offering.
Impact on Patients
This funding will allow NewAmsterdam Pharma Company to continue its research and development efforts to provide effective and well-tolerated medications for patients at risk of cardiovascular disease. The Company’s focus on developing non-statin medicines will offer new options for individuals who do not respond well to existing therapies.
Effect on the World
As NewAmsterdam Pharma Company progresses in its mission to develop innovative treatments, the healthcare industry as a whole stands to benefit. This investment not only signifies confidence in the Company’s potential but also highlights the importance of ongoing research and development in addressing critical health issues.
Conclusion
Overall, the commencement of this public offering is a significant step forward for NewAmsterdam Pharma Company N.V. and the patients it aims to serve. With continued support and investment, the Company is well-positioned to make a meaningful impact in the field of cardiovascular disease treatment.
